Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 5.81B 5.02B 4.69B 4.3B 8.09B 553B 8.22B 55.04B 21.6B 277B 21.81B 21.33B 916B P/E 2026 *
56.6x
P/E 2027 * 34.2x
Enterprise Value 5.81B 5.02B 4.69B 4.3B 8.09B 553B 8.22B 55.04B 21.6B 277B 21.81B 21.33B 916B EV / Sales 2026 *
20x
EV / Sales 2027 * 15.3x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
07/08 RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating MT
07/08 Ligand Pharmaceuticals Incorporated, Q2 2026 Earnings Call, Aug 06, 2026
07/08 Ligand Pharmaceuticals Reaffirms Earnings Guidance for the Year 2026 CI
07/08 Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07/08 Ligand Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Lifted, Revenue Outlook Reaffirmed MT
06/08 (LGND) Ligand Pharmaceuticals Expects 2026 Revenue Range $270M - $310M, vs. FactSet Est of $287.4M MT
06/08 (LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $9.00 to $9.50, vs. FactSet Est of $9.21 MT
06/08 Earnings Flash (LGND) Ligand Pharmaceuticals Incorporated Reports Q2 Revenue $63.7M, vs. FactSet Est of $60.9M MT
06/08 Earnings Flash (LGND) Ligand Pharmaceuticals Incorporated Posts Q2 Adjusted EPS $2.37 per Share, vs. FactSet Est of $1.95 MT
05/08 Ligand Pharmaceuticals Insider Sold Shares Worth $1,444,951, According to a Recent SEC Filing MT
03/08 Oppenheimer Adjusts Ligand Pharmaceuticals PT to $326 From $285, Maintains Outperform Rating MT
15/07 RBC Capital Adjusts Price Target on Ligand Pharmaceuticals to $340 From $262, Maintains Outperform Rating MT
15/07 Agenus Inc. announced that it has received $85 million in funding from RA Capital Management, L.P., Ligand Pharmaceuticals Incorporated, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, Investment Arm CI
1 day-2.33%
1 week+1.95%
Current month+1.95%
1 month-8.23%
3 months+39.38%
6 months+53.93%
Current year+55.05%
1 week 283.77
Extreme 283.77
317.49
1 month 283.77
Extreme 283.77
323.33
Current year 175.89
Extreme 175.89
326.63
1 year 137.14
Extreme 137.14
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 66 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 57 27/09/2006
Director/Board Member 66 01/03/2007
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Fiscal year

General Counsel

15,000 0.0748%
1/7/26 Fiscal year

General Counsel

15,000 0.0748%
30/6/26 Others

Chief Executive Officer

132 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%+1.95%+100.35%+342.16% 5.81B
-0.52%+3.21%+85.02%+161.12% 1,057B
+0.88%+1.13%+51.13%+49.76% 625B
+0.89%-1.95%+23.73%+63.67% 435B
+0.71%+3.87%+47.45%+38.68% 363B
+0.64%-0.49%+35.39%+40.21% 296B
+0.39%-5.83%+8.64%+9.28% 249B
+1.51%+6.69%+44.34%+62.47% 222B
+3.92%-0.46%-1.21%-44.09% 209B
+1.80%+2.30%+20.79%+65.13% 165B
Average +0.95%+0.97%+41.56%+78.84% 362.66B
Weighted average by Cap. +1.12%+1.22%+48.42%+75.76%

Financials

2026 *2027 *
Net sales 290M 251M 234M 215M 404M 27.61B 411M 2.75B 1.08B 13.84B 1.09B 1.07B 45.74B 378M 327M 306M 280M 527M 36.02B 536M 3.59B 1.41B 18.05B 1.42B 1.39B 59.68B
Net income 110M 95.24M 88.94M 81.59M 153M 10.48B 156M 1.04B 410M 5.25B 413M 404M 17.36B 188M 163M 152M 139M 262M 17.89B 266M 1.78B 699M 8.97B 706M 690M 29.65B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
07/08/26 USD 293.15 -2.33% 313,611
06/08/26 USD 300.14 -0.80% 393,774
05/08/26 USD 302.57 +0.59% 197,094
04/08/26 USD 300.79 +3.00% 329,156
03/08/26 USD 292.04 +1.56% 191,741
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
293.15USD
Average target price
343.80USD
Spread / Average Target
+17.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock